doi: 10.1016/0049-3848(85)90244-0.
Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration
- PMID: 4082105
- DOI: 10.1016/0049-3848(85)90244-0
Item in Clipboard
Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration
Thromb Res.
.
No abstract available
Similar articles
-
Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration.Haemostasis. 1986;16(2):116-22. doi: 10.1159/000215281. Haemostasis. 1986. PMID: 3710290 Clinical Trial.
-
A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.Thromb Haemost. 1985 Apr 22;53(2):208-11. Thromb Haemost. 1985. PMID: 4024029
-
Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin.Semin Thromb Hemost. 1985 Jul;11(3):316-7. doi: 10.1055/s-2007-1004384. Semin Thromb Hemost. 1985. PMID: 4048953 Clinical Trial. No abstract available.
-
Pharmacokinetics of low molecular weight heparins.Acta Chir Scand Suppl. 1990;556:57-61. Acta Chir Scand Suppl. 1990. PMID: 1963018 Review.
-
Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin.Acta Chir Scand Suppl. 1990;556:68-74. Acta Chir Scand Suppl. 1990. PMID: 1963020 Review.
Cited by
-
Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.J Thromb Thrombolysis. 1997;4(2):197-205. doi: 10.1023/a:1008870228789. J Thromb Thrombolysis. 1997. PMID: 10639262 No abstract available.
-
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.Clin Pharmacokinet. 2003;42(12):1043-57. doi: 10.2165/00003088-200342120-00003. Clin Pharmacokinet. 2003. PMID: 12959635 Review.
-
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.Drugs. 1995 Mar;49(3):388-410. doi: 10.2165/00003495-199549030-00006. Drugs. 1995. PMID: 7774513 Review.
-
Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis.Thrombosis. 2015;2015:126975. doi: 10.1155/2015/126975. Epub 2015 Oct 12. Thrombosis. 2015. PMID: 26543644 Free PMC article.
-
Syndecans and glycosaminoglycans influence B-cell development and activation.EMBO Rep. 2025 May;26(9):2435-2458. doi: 10.1038/s44319-025-00432-6. Epub 2025 Mar 28. EMBO Rep. 2025. PMID: 40155751 Free PMC article.